My news gathering has come up with a lot of interesting news so I have fac decided to lump it all together....
First up something serious..."EASD 2009 - Lantus defended amid allegations of increased cancer risk"
http://www.pr-inside.com/easd-2009-lantus-defended-amid-r1937915.htm
One thing to pick out amidst the long piece is that long-term implications "may involve a greater focus on reducing the insulin requirements of patients through reductions in beta-cell function decline and insulin sensitivity, rather than using insulin as a panacea to elevated glycated HbA1c levels".
Better news...
Novo Nordisk has launched Victoza (liraglutide), a new drug with ‘four-in-one benefits' for people with Type 2...
http://www.thehindubusinessline.com/2010/06/09/stories/2010060952400200.htm
Good for your BP too!
More good news...
"Vildagliptin effective and well-tolerated add-on to glimepiride"
As some may know Vildagliptin is an effective and well-tolerated add-on therapy to glimepiride for the treatment of Type 2 and the dipeptidyl peptidase-4 inhibitor vildagliptin has previously been shown to significantly improve glycemic control in Type 2 when added to metformin therapy, as reported by MedWire News.
http://www.incirculation.net/NewsIt...d-welltolerated-addon-to-.aspx?usechannel=DIA
Upshot is that vildagliptin 100 mg/day is “an efficacious and well tolerated addition"...
And finally...
"Team Discovers Important New Player In Diabetes Onset - research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion".
http://www.medilexicon.com/medicalnews. ... sid=191110
Apparently they reckon upping levels of ABCG1 may benefit two fold - reducing arterial plaque buildup and in improving insulin production.... 8)
First up something serious..."EASD 2009 - Lantus defended amid allegations of increased cancer risk"
http://www.pr-inside.com/easd-2009-lantus-defended-amid-r1937915.htm
One thing to pick out amidst the long piece is that long-term implications "may involve a greater focus on reducing the insulin requirements of patients through reductions in beta-cell function decline and insulin sensitivity, rather than using insulin as a panacea to elevated glycated HbA1c levels".
Better news...
Novo Nordisk has launched Victoza (liraglutide), a new drug with ‘four-in-one benefits' for people with Type 2...
http://www.thehindubusinessline.com/2010/06/09/stories/2010060952400200.htm
Good for your BP too!
More good news...
"Vildagliptin effective and well-tolerated add-on to glimepiride"
As some may know Vildagliptin is an effective and well-tolerated add-on therapy to glimepiride for the treatment of Type 2 and the dipeptidyl peptidase-4 inhibitor vildagliptin has previously been shown to significantly improve glycemic control in Type 2 when added to metformin therapy, as reported by MedWire News.
http://www.incirculation.net/NewsIt...d-welltolerated-addon-to-.aspx?usechannel=DIA
Upshot is that vildagliptin 100 mg/day is “an efficacious and well tolerated addition"...
And finally...
"Team Discovers Important New Player In Diabetes Onset - research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion".
http://www.medilexicon.com/medicalnews. ... sid=191110
Apparently they reckon upping levels of ABCG1 may benefit two fold - reducing arterial plaque buildup and in improving insulin production.... 8)
